Skip to main content
Top
Published in: European Archives of Oto-Rhino-Laryngology 4/2020

01-04-2020 | Propranolol | Otology

Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug

Authors: E. Domínguez-Durán, M. A. Montilla-Ibáñez, M. G. Álvarez-Morujo de Sande, E. Domènech-Vadillo, C. Bécares-Martínez, R. González-Aguado, G. Guerra-Jiménez

Published in: European Archives of Oto-Rhino-Laryngology | Issue 4/2020

Login to get access

Abstract

Introduction

Vestibular migraine (VM) consists of recurrent episodes of vestibular symptoms that are accompanied by migraine in at least 50% of the episodes. The criteria of the Bárány Society include two diagnostic categories: “actual” vestibular migraine and probable vestibular migraine. There is a wide range of drugs that can be prescribed for the prophylactic treatment of VM, but recommendations for the selection of the most appropriate drug are currently lacking.

Objective

To measure the extent to which the prophylactic treatment of VM reduces vestibular symptoms, headache and the number of crises depending on the diagnostic category of the Bárány Society and the drug used for prophylaxis.

Material and methods

This is a multicenter prospective study. Patients with VM who presented to any of the participating centers and who subsequently met the VM criteria were prescribed one of the following types of prophylaxis: acetazolamide, amitriptyline, flunarizine, propranolol or topiramate. Patients were called back for a follow-up visit 5 weeks later. This allowed the intensity of vestibular symptoms, headache and the number of crises before and during treatment to be compared.

Results

31 Patients met the inclusion criteria. During the treatment, all the measured variables decreased significantly. In a visual analogue scale, the intensity of vestibular symptoms decreased by 45.8 points, the intensity of headache decreased by 47.8 points and patients suffered from 15.6 less monthly crises compared to the period before the treatment. No significant between-group differences were found when patients were divided based on their diagnostic category or the choice of prophylaxis prescribed to them.

Conclusion

The treatment of VM produces a reduction of symptoms and crises with no significant differences based on patients’ diagnostic categories or the choice of prophylaxis prescribed to them.
Literature
1.
go back to reference Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J et al (2012) Vestibular migraine: diagnostic criteria. J Vestib Res Equilib Orientat 22(4):167–172CrossRef Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J et al (2012) Vestibular migraine: diagnostic criteria. J Vestib Res Equilib Orientat 22(4):167–172CrossRef
2.
go back to reference Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T et al (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67(6):1028–1033CrossRef Neuhauser HK, Radtke A, von Brevern M, Feldmann M, Lezius F, Ziese T et al (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67(6):1028–1033CrossRef
3.
go back to reference Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache 38(1):1–211. Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia Int J Headache 38(1):1–211.
4.
go back to reference Maldonado Fernández M, Birdi JS, Irving GJ, Murdin L, Kivekäs I, Strupp M (2015) Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev. 21(6):CD010600. Maldonado Fernández M, Birdi JS, Irving GJ, Murdin L, Kivekäs I, Strupp M (2015) Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev. 21(6):CD010600.
6.
go back to reference Salviz M, Yuce T, Acar H, Karatas A, Acikalin RM (2016) Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. The Laryngoscope 126(1):169–174CrossRef Salviz M, Yuce T, Acar H, Karatas A, Acikalin RM (2016) Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial. The Laryngoscope 126(1):169–174CrossRef
7.
go back to reference Salmito MC, Duarte JA, Morganti LOG, Brandão PVC, Nakao BH, Villa TR et al (2017) Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol 83(4):404–410CrossRef Salmito MC, Duarte JA, Morganti LOG, Brandão PVC, Nakao BH, Villa TR et al (2017) Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol 83(4):404–410CrossRef
8.
go back to reference Liu F, Ma T, Che X, Wang Q, Yu S (2017) The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol 8:524CrossRef Liu F, Ma T, Che X, Wang Q, Yu S (2017) The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine. Front Neurol 8:524CrossRef
9.
go back to reference Domínguez-Durán E, Baños-López P, Martín-Castillo E, Galera-Ruiz H (2019) Inter-rater agreement in the choice of prophylactic treatment for vestibular migraine and role of an assisted algorithm for this choice. Acta Otorrinolaringol Esp Domínguez-Durán E, Baños-López P, Martín-Castillo E, Galera-Ruiz H (2019) Inter-rater agreement in the choice of prophylactic treatment for vestibular migraine and role of an assisted algorithm for this choice. Acta Otorrinolaringol Esp
10.
go back to reference Domínguez-Durán E, Baños-López P, Martín-Castillo E (2019) Migratron: Algoritmo asistido para la elección de tratamiento profiláctico en la migraña vestibular. https://migratron.com/#/. Accessed 5 Jan 2019 Domínguez-Durán E, Baños-López P, Martín-Castillo E (2019) Migratron: Algoritmo asistido para la elección de tratamiento profiláctico en la migraña vestibular. https://​migratron.​com/​#/​. Accessed 5 Jan 2019
11.
go back to reference Zhao PP, Xu XR, Jin ZG, Zhang Y, Li YJ (2019) Analysis of clinical features of secondary benign paroxysmal positional vertigo. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi J Clin Otorhinolaryngol Head Neck Surg 33(3):220–224 Zhao PP, Xu XR, Jin ZG, Zhang Y, Li YJ (2019) Analysis of clinical features of secondary benign paroxysmal positional vertigo. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi J Clin Otorhinolaryngol Head Neck Surg 33(3):220–224
12.
go back to reference von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D et al (2015) Benign paroxysmal positional vertigo: diagnostic criteria. J Vestib Res Equilib Orientat 25(3–4):105–117CrossRef von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D et al (2015) Benign paroxysmal positional vertigo: diagnostic criteria. J Vestib Res Equilib Orientat 25(3–4):105–117CrossRef
13.
go back to reference Álvarez-Morujo de Sande MG, González-Aguado R, Guerra-Jiménez G, Domènech-Vadillo E, Galera-Ruiz H, Figuerola-Massana E et al (2019) Probable benign paroxysmal positional vertigo, spontaneously resolved: incidence in medical practice, patients’ characteristics and the natural course. J Otol 14(3):111–116CrossRef Álvarez-Morujo de Sande MG, González-Aguado R, Guerra-Jiménez G, Domènech-Vadillo E, Galera-Ruiz H, Figuerola-Massana E et al (2019) Probable benign paroxysmal positional vertigo, spontaneously resolved: incidence in medical practice, patients’ characteristics and the natural course. J Otol 14(3):111–116CrossRef
14.
go back to reference von Brevern M, Radtke A, Clarke AH, Lempert T (2004) Migrainous vertigo presenting as episodic positional vertigo. Neurology 62(3):469–472CrossRef von Brevern M, Radtke A, Clarke AH, Lempert T (2004) Migrainous vertigo presenting as episodic positional vertigo. Neurology 62(3):469–472CrossRef
15.
go back to reference Mallery RM, Friedman DI, Liu GT (2014) Headache and the pseudotumor cerebri syndrome. Curr Pain Headache Rep 18(9):446CrossRef Mallery RM, Friedman DI, Liu GT (2014) Headache and the pseudotumor cerebri syndrome. Curr Pain Headache Rep 18(9):446CrossRef
16.
go back to reference Stevens SM, Rizk HG, Golnik K, Andaluz N, Samy RN, Meyer TA et al (2018) Idiopathic intracranial hypertension: contemporary review and implications for the otolaryngologist. The Laryngoscope 128(1):248–256CrossRef Stevens SM, Rizk HG, Golnik K, Andaluz N, Samy RN, Meyer TA et al (2018) Idiopathic intracranial hypertension: contemporary review and implications for the otolaryngologist. The Laryngoscope 128(1):248–256CrossRef
17.
go back to reference Lopez-Escamez JA, Carey J, Chung W-H, Goebel JA, Magnusson M, Mandalà M et al (2015) Diagnostic criteria for Menière’s disease. J Vestib Res Equilib Orientat 25(1):1–7CrossRef Lopez-Escamez JA, Carey J, Chung W-H, Goebel JA, Magnusson M, Mandalà M et al (2015) Diagnostic criteria for Menière’s disease. J Vestib Res Equilib Orientat 25(1):1–7CrossRef
18.
go back to reference Strupp M, Lopez-Escamez JA, Kim J-S, Straumann D, Jen JC, Carey J et al (2016) Vestibular paroxysmia: diagnostic criteria. J Vestib Res Equilib Orientat 26(5–6):409–415 Strupp M, Lopez-Escamez JA, Kim J-S, Straumann D, Jen JC, Carey J et al (2016) Vestibular paroxysmia: diagnostic criteria. J Vestib Res Equilib Orientat 26(5–6):409–415
Metadata
Title
Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug
Authors
E. Domínguez-Durán
M. A. Montilla-Ibáñez
M. G. Álvarez-Morujo de Sande
E. Domènech-Vadillo
C. Bécares-Martínez
R. González-Aguado
G. Guerra-Jiménez
Publication date
01-04-2020
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology / Issue 4/2020
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-020-05802-5

Other articles of this Issue 4/2020

European Archives of Oto-Rhino-Laryngology 4/2020 Go to the issue